Representative immunoblots of HER3 and downstream signaling are depicted in Fig. 2D. As expected, we found that the PI3K/AKT pathway was predominantly activated in HER3+ breast cancer compared to HER3- breast cancer. This evidence concerns the gene ERBB3 and breast cancer.